Results
| Results, n (%) | axSpA (n=32, 60%) | PsA (n=21, 40%) |
|---|---|---|
| Positive ADAbs, n (%), median (IQR) AU/mL | 12 (37), 46.5 (18–74) | 8 (38), 86.5 (29–212) |
| Therapeutic drug levels, n (%) | 14 (44) | 10 (48) |
| High ADAbs and very low or undetectable drug (likely drug-neutralising), n (%) | 4 (13) | 4 (27) |
| Drug discontinuation (no alternative biologic required), n (%) | 1 (3) | 2 (10) |
| Dose reduced or interval extended, n (%) | 8 (25) | 3 (14) |
| Change to alternative biologic (either within the same class or to a different mode of action biologic), n (%) | 1 (3) | 3 (14) |
| Switched to biosimilar, n (%) | 14 (44) | 10 (48) |
ADAbs = anti-drug antibodies; axSpA = Axial spondyloarthritis; PsA = psoriatic arthritis.